Evidence map›Paper›PMID 30655980›Full record

ArticleMolecular and clinical oncology2019

Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.

Hiroko Ito, Mitsuaki Ishida, Kaori Sando, Kimiaki Okano, Yusuke Ebisu, Takuo Fujisawa, Hiroshi Iwai, Koji Tsuta

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hiroko ItoDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Mitsuaki IshidaDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Kaori SandoDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Kimiaki OkanoDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Yusuke EbisuDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Takuo FujisawaDepartment of Otolaryngology, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Hiroshi IwaiDepartment of Otolaryngology, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Koji TsutaDepartment of Pathology and Laboratory Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Kansai Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salivary duct carcinoma (SDC) is a relatively rare highly aggressive salivary gland tumor. Although SDC shows frequent lymph node and distant metastases, the presence of neoplastic cells in the pleural effusion is extremely rare. In this report, we describe the first documented cytological case of metastatic SDC in cardiac and pleural effusions with immunocytochemical analyses for androgen receptor (AR) and human epidermal growth factor receptor (HER)2. A 52-year-old Japanese male developed cardiac tamponade and respiratory discomfort after surgery and chemo-radiation therapy for SDC of the right submandibular gland. Aspiration of the cardiac and pleural effusions was performed. The Papanicolaou-stained cytological specimens of cardiac and pleural effusions showed that numerous small ball-like or papillary structures were present in an inflammatory background. The neoplastic cells had rich granular cytoplasm and large round to oval nuclei containing conspicuous nucleoli. Immunocytochemical analyses clearly demonstrated positivity for AR and strong membranous expression of HER2 in the neoplastic cells. Accordingly, a cytodiagnosis of metastatic SDC was made. Recently, HER2-targeted or AR deprivation therapy have been introduced for patients with SDC, therefore, determination of expression profiles of AR and HER2 may be crucial for developing a treatment strategy for patients with metastatic SDC. According to the results of the present report, immunocytochemical analyses for AR and HER2 in the effusion specimens may be useful for determination of a treatment strategy for patients with metastatic SDC.

Indexed as

androgen receptorcardiac effusionhuman epidermal growth factor receptor 2pleural effusionsalivary duct carcinoma

Identifiers

PMID30655980
PMCPMC6313956
OpenAlexW2897128952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.